Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax plus low-dose cytarabine versus placebo plus low-dose cytarabine in previously untreated AML patients unfit for intensive chemotherapy
CTR20171499Phase 3Active
- Sponsor
- AbbVie Inc.
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of venetoclax in acute myeloid leukemia (AML), sponsored by AbbVie Inc.. Started Aug 2018; status: active.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on CTR20171499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171499.